With orphan drug status was certainly quickest path to income to fund all the other clinical trials they would like to do. Rate of cash burn is already higher than I'd like to see.
Sentiment: Strong Buy
oooh very scary. I'm going to exit this ohterwise exciting prospect exactly for the reasons you exceedingly cite.
Pretty interesting how hard the pumping continues. And its pretty much a joke too with "news" reports consisting entirely of old news. It's either a desperation move, or more sinisterly, Cramer & collaborators drove it done so they can drive it back up. Either way, not necessarily a bad thing if you are long and didn't get shaken out.
pretty much an endless stream of rehashed pumps, and of course, these are unbiased heartfelt benevolent selfless gifts to us:
This Latest Study Adds 1 More Piece to the Alzheimer's Puzzle at Motley Fool (Sun, Aug 2)
The Blockbuster Potential of Biogen Inc's Pipelineat Motley Fool(Sat, Aug 1)
Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity at Motley Fool(Thu, Jul
hey I see that yesterday was not a particularly good day in the life of CTIC relative to most. stock price - more dilution, a stock split and more lies must be on the way...